Saniona
SANION · Nasdaq Stockholm · Denmark / Sweden
Public Market Listing
SANIONNasdaq Stockholm
Live quotes, historical charts, and market capitalization for Saniona are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
TesofensineNo recent activity | Phase 3 | Noradrenaline/dopamine/serotonin reuptakeSmall molecule | Obesity |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (1)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q4 | $0.5M | — | $63M | $5.0M | report ↗ |
Saniona reported revenue of $0.49M, down 98.5% YoY, cash and equivalents of $63.14M, and a quarterly net burn of $4.95M for Q4 2025.
Figures only: this period's report disclosed no narrative text
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $44M | — | $63M | — | report ↗ |
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $32M | — | $28M | — | report ↗ |